Zobrazeno 1 - 10
of 18
pro vyhledávání: '"S M, Foord"'
Publikováno v:
The Journal of pharmacology and experimental therapeutics. 294(1)
Receptor activity modifying proteins (RAMPs) constitute a group of three proteins, designated as RAMP1, 2, and 3, which are able to effect functional changes in some members of the G protein-coupled receptor family. Thus, RAMP1 or RAMP3 can modify th
Autor:
I J, Beresford, C, Browning, S J, Starkey, J, Brown, S M, Foord, J, Coughlan, P C, North, M L, Dubocovich, R M, Hagan
Publikováno v:
The Journal of pharmacology and experimental therapeutics. 285(3)
N-[2-[2,3,7,8-tetrahydro-1H-furo(2,3-g)indol-1-yl]ethyl]acetamide (GR196429) is a novel, nonindolic melatonin receptor agonist. GR196429 had high affinity for human mt1 (pKi 9.9) and MT2 (pKi 9.8) receptors expressed in Chinese hamster ovary cells an
Publikováno v:
British journal of pharmacology. 121(8)
1. The human prostaglandin EP4 receptor has been expressed by use of the Semliki Forest virus system. 2. In cell membranes [3H]-prostaglandin E2 ([3H]-PGE2) bound to a high affinity site with a Kd of 1.12 +/- 0.3 nM and a Bmax of 3.1 +/- 0.3 pmol mg-
Autor:
S. M. Foord
Publikováno v:
Science Signaling. 2003:pe25-pe25
Autor:
John R. Peters, M. D. Rodriguez-Arnao, Reginald Hall, A. Gomez-Pan, Carlos Dieguez, Robert G. Newcombe, S. M. Foord, Maurice F. Scanlon, C. Edwards
Publikováno v:
The Journal of Clinical Endocrinology & Metabolism. 57:975-980
In order to delineate more accurately the dopaminergic control of anterior pituitary function in normal subjects and in patients with pathological hyperprolactinemia, we investigated the nature of the circadian variation in the dopaminergic inhibitio
Autor:
R. Hall, R. Valcavi, John R. Peters, S. M. Foord, P. J. Evans, P. E. Harris, C. Dieguez, Maurice F. Scanlon
Publikováno v:
Clinical Endocrinology. 23:139-146
SUMMARY The effects of oestrogen priming on the response of serum PRL, LH and TSH to dopamine (DA) infusion have been studied in hyperprolactinaemia. Seven hyperprolactinaemic females (aged 22–57 years; basal PRL 911–5130 mU/1, normal >420 mU/1),
Autor:
S. M. Foord, John R. Peters, C. Dieguez, C. Edwards, P. E. Harris, Maurice F. Scanlon, J. Salvador, D. W. Wilson, R. Hall
Publikováno v:
Clinical Endocrinology. 22:265-272
Pharmacological doses of glucocorticoids inhibit TSH release both in vivo and in vitro and since the circadian rhythms of TSH and cortisol show a reciprocal relationship, the hypothesis has been advanced that changes in cortisol levels may be a prima
Autor:
Randolph W. Hall, A. Gomez-Pan, S. M. Foord, V. Jordan, P. E. Harris, Carlos Dieguez, Maurice F. Scanlon, M. D. Rodriguez-Arnao
Publikováno v:
Journal of Endocrinology. 109:53-56
In order to investigate whether the impaired GH secretion associated with hypothyroidism and hyperthyroidism is due to a hypothalamic or a pituitary disorder, we have studied plasma GH responses to GH-releasing factor (1–29) (GRF) in euthyroid, hyp
Publikováno v:
Endocrinology. 117(2)
TSH responses to adrenergic agonists have been measured in 3-day monolayer cultures of euthyroid and hypothyroid male rat anterior pituitary (AP) cells. Responses were qualitatively similar in that (-)epinephrine and (-)norepinephrine had the same ED
Publikováno v:
Endocrinology. 118(4)
The effect of conditioned vs. fresh culture medium on the dopaminergic inhibition of TSH and PRL secretion by primary cultures of male rat anterior pituitary cells has been studied. In the presence of conditioned medium (that had been in contact with